Publications by authors named "Jennifer Tullai"
Article Synopsis
- Malignant tumors can avoid the immune system's attacks by luring in regulatory T cells (Treg), and the IKZF2 (Helios) transcription factor is essential for Treg cell stability and function.
- The study introduces NVP-DKY709, a new drug that specifically targets and degrades IKZF2 while leaving other related factors (IKZF1/3) intact, enhancing the immune response against tumors.
- In tests, NVP-DKY709 not only improved the activity of T-effector cells and reduced tumor growth in mice but is also being explored for its potential as a cancer treatment in clinical trials.
Englerin A is a structurally unique natural product reported to selectively inhibit growth of renal cell carcinoma cell lines. A large scale phenotypic cell profiling experiment (CLiP) of englerin A on ¬over 500 well characterized cancer cell lines showed that englerin A inhibits growth of a subset of tumor cell lines from many lineages, not just renal cell carcinomas. Expression of the TRPC4 cation channel was the cell line feature that best correlated with sensitivity to englerin A, suggesting the hypothesis that TRPC4 is the efficacy target for englerin A.
View Article and Find Full Text PDFWe investigated the significance of erythropoietin receptor (EPOR) expression following treatment with recombinant human erythropoietin (rHuEPO; epoetin alpha) and the effect of recombinant epoetins (epoetin alpha, epoetin beta, and darbepoetin alpha) alone or in combination with anticancer therapy on tumor growth in two well-established preclinical models of breast carcinoma (MDA-MB-231 and MCF-7 cell lines). Expression and localization of EPOR under hypoxic and normoxic conditions in MDA-MB-231 and MCF-7 cells were evaluated by immunoblotting, flow cytometry, and immunohistochemistry. EPOR binding was evaluated using [125I]rHuEPO.
View Article and Find Full Text PDF